Zika Virus Gene Replikins: Significant Mutations Detected

Surveillance Service and Delivery in 7-Days of New Commensurate 'Made to Measure' Vaccine-Blocker Candidates

News provided by

Replikins Ltd.

Jul 11, 2016, 04:53 ET

TORONTO, July 11, 2016 /PRNewswire/ -- Replikins Ltd. announced today that recent rapid significant Zika virus gene mutations have been detected and quantified by Replikins Surveillance™ software. The data predicts Zika intensification and spread of outbreaks in the coming year.

Logo - http://photos.prnewswire.com/prnh/20160711/388452LOGO

Replikins changes in the structure of virus genes represent mutations correlated with rapid replication of the virus.

Obtained by daily quantitative automated software analysis of all Zika specimens gene sequences on PubMed, rising Replikin Counts one year before the outbreak and continuing with no marked drop are associated with and predict further outbreaks and spread of Zika, as in the case of over 3 million sequence analyses to date for 41 outbreaks by 16 other viruses (1-2). The sudden cessation of the Ebola 2014 outbreak was predicted by a sudden drop in the Gene Replikin Count of Ebola (3).

With significant virus gene mutations, previous vaccine formulations may be outdated and less effective. The company (4) has incorporated up-to-date mutation changes in its current Replikins vaccine-blocker candidate formulations.

For 1) up to date mutation information in a given geographic area to be performed by Replikins Surveillance Service™, and 2) based on 1), 'made to measure' Replikins Synthetic Zika Vaccine™ candidates manufactured in 7 days for delivery freeze-dried.

Contact:  Samuel Bogoch, Email; 646-320-5910.

References:

  1. Bogoch,S. and Bogoch,ES. Replikins. The Chemistry of Rapid Replication. Begell Press, New York, 2005.  
  2. Bogoch,S. and Bogoch,ES. Prediction of specific virus outbreaks made from increased concentration of a new class of virus genomic peptides, replikins.Nature precedings doi:10.1038/npre.2011.6279.1 
  3. Submitted to The Lancet for publication, October 15, 2014; google "Reuters Replikins". 
  4. Jackwood et al. Efficacy of a Replikin Peptide Vaccine Against Low Pathogenicity Avian Influenza H5 Virus, Avian Diseases 53(4): 613‐617, 2009.

SOURCE Replikins Ltd.